They completed a trial on muscle soreness following intense exercises so if the trial was positive then I imagine it can be marketed for any muscle soreness. The ankle sprain trial allows them to expand the indications for the label & gives them a second efficacy trial to support approval.
There is a number of competing products but sales must be huge. Prescriptions for Endo’s product Voltaren® gel ramped quickly, achieving close to 300,000 prescriptions per month by December 2011.
Loko, one problem with your idea. Whose going to pay for sq MTX in the trials. Insurance companies are not in the business of funding CT's & ATRS lacks the funds.
Chartreux, I inject MTX weekly and I dont pay anywhere near that even without insurance. I think its about 80$ for a two month supply but the caveat is that I have to use a regular syringe and I get small bottles of MTX and I inject in my butt but I am sure that it could just as easily be injected to the stomach without much effort as long as the needle was a small enough gauge. MTX is available in 2ml bottles that are a one time use (no preservatives).
I had this conversation with my Doctor last visit because I was not able to refill my MTX script due to it being unavailable a few months back. She told me the reason was due to this new auto injectible that they are charging so much money for. She is extremely upset because she has several patients who inject MTX and are not able to afford any of the biologics or this new injectible MTX pen. She thinks they are gouging everyone and I would have to agree. I wonder if the insurance co's are not wanting to cover it because of this or something... Take care
I've still got a position in CYNAF. I don't like a number of things with the company but its worth holding a small position in case someone takes them out. They changed auditors this week so their either getting the books in order for a buyout down the line or uplisting.
I've got 3K shares in ACAD but holding Dec/25 calls against that position. I sold calls against that position since I don't see it trading over $30 without a buyout. I got $5.90 on some of those shares so I hope the stock drifts a little lower & I'm not called away.
Holding positions in ARWR, INCY, ENTA. Hoping one of them hits before year end.
SRPT - They have management & credibility problems so I've been scared to hold a position. Friday tweets indicated the start of their confirmatory trial has been delayed.
The problem continues to be the same. - If you had rheumatoid arthritis & oral methotrexate was not working then what drug would you want as the next alternative?
The stocks down more then ATRS.
You sound like someone whose lost a bunch of money on this stock. Don't blame me for your poor investment decisions.
I spend very little time on the board but people like you give me reason to keep posting.
I'm a nurse anesthetist. I challenge you to do some research on my profession before you talk out your tail like so many on this board.
QST won't be the first choice for most individuals once an oral option is available. QST will be more expensive then gels so the market will be limited to a sub-group. Its the same story with Otrexup. Yes, it can succeed in the market but its not a slam dunk.
I know your going to tell me how big the market is but I heard the same thing with Otrexup & the launch can only be described as steady.
I'm not desperate, there's just a lot going on with testosterone products this week.
Clarus approval would be negative for several reasons.
1. The whole argument of cross transference goes out the window.
2. I'd rather use SQ then gels but I'd rather take an oral then SQ.
If the FDA asks for a post-marketing CV study then I imagine the same thing would happen with QST.
All of us know the efficacy of oral testosterone products are not as good as SQ but it would potentially slow the uptake of QST.